Cardlytics, Inc. (CDLX)
NASDAQ: CDLX · Real-Time Price · USD
0.9035
-0.0110 (-1.20%)
May 4, 2026, 10:43 AM EDT - Market open

Cardlytics Earnings Call Transcripts

Fiscal Year 2025

  • 2025 saw a strategic reset with improved operational efficiency, positive Adjusted EBITDA, and strong U.K. growth, despite revenue declines from the Bank of America exit and content restrictions. The Bridg sale will strengthen liquidity, and sequential growth is expected later in 2026.

  • Q3 2025 saw a 20% drop in billings and 22% revenue decline due to a major FI partner's content block, but margins improved and cost reductions were significant. U.K. revenue grew 22%, and new partnerships and product innovations are expected to drive future growth. Q4 guidance anticipates continued top-line pressure but positive adjusted EBITDA.

  • Q2 2025 results exceeded adjusted EBITDA guidance despite a 5.7% billings decline, with record contribution margin and strong U.K. growth. Major content restrictions by the largest FI partner will drive a 15%-22% year-over-year billings drop in Q3, but diversification and cost controls are underway.

  • Q1 2025 results exceeded guidance despite a 7.3% drop in billings and 8.4% revenue decline, with strong consumer spending in core categories and new partner launches. Cost controls, a 15% workforce reduction, and expanded liquidity position the company for sequential improvement in adjusted EBITDA.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Powered by